Paul Brunetta

9.1k total citations · 3 hit papers
30 papers, 3.7k citations indexed

About

Paul Brunetta is a scholar working on Rheumatology, Pulmonary and Respiratory Medicine and Nephrology. According to data from OpenAlex, Paul Brunetta has authored 30 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Rheumatology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Nephrology. Recurrent topics in Paul Brunetta's work include Systemic Lupus Erythematosus Research (14 papers), Vasculitis and related conditions (10 papers) and Renal Diseases and Glomerulopathies (9 papers). Paul Brunetta is often cited by papers focused on Systemic Lupus Erythematosus Research (14 papers), Vasculitis and related conditions (10 papers) and Renal Diseases and Glomerulopathies (9 papers). Paul Brunetta collaborates with scholars based in United States, United Kingdom and Netherlands. Paul Brunetta's co-authors include David Zhang, Kevin Latinis, Jay Garg, Richard Furie, Brad H. Rovin, Romeo Maciuca, Fernando C. Fervenza, Caroline Gordon, R. John Looney and Gerald B. Appel and has published in prestigious journals such as Endocrinology, Journal of the American Society of Nephrology and Science Translational Medicine.

In The Last Decade

Paul Brunetta

30 papers receiving 3.6k citations

Hit Papers

Efficacy and safety of rituximab in patients with active ... 2009 2026 2014 2020 2012 2009 2022 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
    2012 972 citations Brad H. Rovin, Richard Furie et al. Arthritis & Rheumatism profile →
  2. Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
    2009 972 citations Joan T. Merrill, C. Michael Neuwelt et al. Arthritis & Rheumatism profile →
  3. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
    2022 237 citations Richard Furie, Gustavo Aroca et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Brunetta United States 18 2.6k 1.7k 1.2k 696 593 30 3.7k
Romeo Maciuca United States 13 1.6k 0.6× 1.3k 0.7× 753 0.6× 358 0.5× 280 0.5× 29 2.5k
Edward M Vital United Kingdom 34 2.6k 1.0× 2.0k 1.1× 995 0.8× 140 0.2× 303 0.5× 147 3.9k
Frédéric Houssiau Belgium 24 2.3k 0.9× 1.2k 0.7× 438 0.4× 410 0.6× 174 0.3× 45 3.1k
Lilia Pineda United States 11 2.3k 0.9× 1.8k 1.1× 1.1k 1.0× 207 0.3× 135 0.2× 17 3.0k
Andreas Jönsen Sweden 37 2.6k 1.0× 2.5k 1.5× 638 0.5× 247 0.4× 188 0.3× 105 3.9k
G. Balestrieri Italy 37 3.2k 1.3× 1.6k 0.9× 760 0.6× 661 0.9× 487 0.8× 85 4.2k
María Laura Bertolaccini United Kingdom 37 3.8k 1.5× 985 0.6× 744 0.6× 586 0.8× 287 0.5× 88 4.6k
Elena Raschi Italy 35 2.6k 1.0× 1.4k 0.8× 388 0.3× 528 0.8× 301 0.5× 67 3.9k
Enrique de Ramón Spain 20 2.1k 0.8× 1.3k 0.8× 478 0.4× 314 0.5× 142 0.2× 51 3.1k
Ilaria Cavazzana Italy 34 1.8k 0.7× 956 0.6× 397 0.3× 187 0.3× 332 0.6× 107 3.5k

Countries citing papers authored by Paul Brunetta

Since Specialization
Citations

This map shows the geographic impact of Paul Brunetta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Brunetta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Brunetta more than expected).

Fields of papers citing papers by Paul Brunetta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Brunetta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Brunetta. The network helps show where Paul Brunetta may publish in the future.

Co-authorship network of co-authors of Paul Brunetta

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Brunetta. A scholar is included among the top collaborators of Paul Brunetta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Brunetta. Paul Brunetta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Furie, Richard, Gustavo Aroca, Matthew D. Cascino, et al.. (2022). B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases. 81(1). 100–107. 237 indexed citations breakdown →
3.
Owczarczyk, Kasia, Matthew D. Cascino, Cécile Holweg, et al.. (2020). Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. JCI Insight. 5(18). 9 indexed citations
4.
Rovin, Brad H., Gustavo Aroca, Analía Álvarez, et al.. (2020). Two-Year Results from a Randomized, Controlled Study of Obinutu-zumab for Proliferative Lupus Nephritis. Journal of the American Society of Nephrology. 31(10S). 53–53. 8 indexed citations
5.
Kronbichler, Andreas, Johannes Leierer, Jae Il Shin, et al.. (2019). Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis & Rheumatology. 71(11). 1888–1893. 20 indexed citations
6.
Berti, Alvise, Roscoe L. Warner, Kent J. Johnson, et al.. (2018). Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis & Rheumatology. 70(7). 1114–1121. 48 indexed citations
7.
Berger, Joseph R., et al.. (2018). Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. Journal of NeuroVirology. 24(3). 323–331. 95 indexed citations
8.
Cascino, Matthew D., Jay Garg, Tamiko R. Katsumoto, et al.. (2018). Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. Clinical Journal of the American Society of Nephrology. 13(10). 1502–1509. 104 indexed citations
9.
Garg, Jay, et al.. (2017). SAT0242 Measures of peripheral blood b-cell depletion predict renal response in patients with lupus nephritis treated with rituximab. Annals of the Rheumatic Diseases. 76. 865–865. 1 indexed citations
10.
Miloslavsky, Eli M., Ray Naden, J. W. J. Bijlsma, et al.. (2016). Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Annals of the Rheumatic Diseases. 76(3). 543–546. 141 indexed citations
11.
Cartin‐Ceba, Rodrigo, Ulrich Specks, John H. Stone, et al.. (2016). The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis & Rheumatology. 69(1). 169–175. 16 indexed citations
12.
Unizony, Sebastian, Miguel Villarreal, Eli M. Miloslavsky, et al.. (2015). Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Annals of the Rheumatic Diseases. 75(6). 1166–1169. 173 indexed citations
13.
Geetha, Duvuru, Cees G. M. Kallenberg, John H. Stone, et al.. (2014). Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. Journal of Nephrology. 28(1). 17–27. 19 indexed citations
14.
Geetha, Duvuru, Ulrich Specks, John H. Stone, et al.. (2014). Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. Journal of the American Society of Nephrology. 26(4). 976–985. 123 indexed citations
15.
Rovin, Brad H., Samir V. Parikh, Lee A. Hebert, et al.. (2012). Lupus Nephritis. Clinical Journal of the American Society of Nephrology. 8(1). 147–153. 37 indexed citations
16.
Rovin, Brad H., Richard Furie, Kevin Latinis, et al.. (2012). Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis & Rheumatism. 64(4). 1215–1226. 972 indexed citations breakdown →
17.
Lai, Jin‐Shei, Jennifer L. Beaumont, Sarika Ogale, Paul Brunetta, & David Cella. (2011). Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale in Patients with Moderately to Severely Active Systemic Lupus Erythematosus, Participating in a Clinical Trial. The Journal of Rheumatology. 38(4). 672–679. 110 indexed citations
18.
Pelletier, Elise M., Sarika Ogale, Elaine Yu, Paul Brunetta, & Jay Garg. (2009). Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: Results from an analysis of data from a US claims database. Clinical Therapeutics. 31(11). 2653–2664. 58 indexed citations
19.
Merrill, Joan T., C. Michael Neuwelt, Daniel J. Wallace, et al.. (2009). Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis & Rheumatism. 62(1). 222–233. 972 indexed citations breakdown →
20.
Beaumont, Jennifer L., et al.. (2009). PSY49 VALIDATION OF THE SF-36 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). Value in Health. 12(7). A384–A384. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Romeo Maciuca Breakdown of academic impact, for papers by Edward M Vital Breakdown of academic impact, for papers by Frédéric Houssiau Breakdown of academic impact, for papers by Lilia Pineda Breakdown of academic impact, for papers by Andreas Jönsen Breakdown of academic impact, for papers by G. Balestrieri Breakdown of academic impact, for papers by María Laura Bertolaccini Breakdown of academic impact, for papers by Elena Raschi Breakdown of academic impact, for papers by Enrique de Ramón Breakdown of academic impact, for papers by Ilaria Cavazzana
Rankless by CCL
2026